<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005605</url>
  </required_header>
  <id_info>
    <org_study_id>NU 95B2</org_study_id>
    <secondary_id>NU-95B2</secondary_id>
    <secondary_id>NCI-G00-1737</secondary_id>
    <nct_id>NCT00005605</nct_id>
  </id_info>
  <brief_title>Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer</brief_title>
  <official_title>Does Tamoxifen Prevent the Skeletal and Cardiovascular Morbidity of Chemotherapy in Premenopausal Women?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Tamoxifen may be able to increase bone density and decrease cholesterol in women&#xD;
      who are undergoing chemotherapy for breast cancer.&#xD;
&#xD;
      PURPOSE: Clinical trial to study the effectiveness of tamoxifen in preventing bone loss and&#xD;
      heart disease caused by chemotherapy treatment in premenopausal women who have stage I or&#xD;
      stage II breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the bone density in the femoral neck and lumbar spine and cholesterol levels in&#xD;
           premenopausal women with stage I or II breast cancer treated with adjuvant chemotherapy&#xD;
           with or without tamoxifen.&#xD;
&#xD;
        -  Collect information regarding breast cancer risk factors, treatment, pathology, diet,&#xD;
           activity levels, weight, and smoking in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to type of treatment (adjuvant chemotherapy plus&#xD;
      tamoxifen vs adjuvant chemotherapy alone).&#xD;
&#xD;
      Patients receive adjuvant chemotherapy with or without oral tamoxifen at the discretion of&#xD;
      the treating physician.&#xD;
&#xD;
      Prior to starting chemotherapy, patients undergo blood draw to measure baseline levels of&#xD;
      follicle-stimulating hormone, estradiol, total cholesterol, high-density lipoproteins, and&#xD;
      low-density lipoproteins. Patients undergo baseline bone densitometry of the femoral neck and&#xD;
      lumbar spine to assess bone density prior to starting chemotherapy or within 30 days of the&#xD;
      first drug treatment. Laboratory studies and bone densitometry are repeated at years 1 and 2.&#xD;
      A comparison is made between the study findings at baseline and at years 1 and 2.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients (40 per stratum) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">79</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Tamoxifen group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy group</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stage I or II breast cancer currently undergoing treatment with either&#xD;
        chemotherapy or tamoxifen.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven stage I or II breast cancer&#xD;
&#xD;
          -  Must be scheduled to receive adjuvant chemotherapy with or without tamoxifen&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  35 to 50&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Premenopausal by follicle-stimulating hormone and estradiol levels&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seema A. Khan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 18, 2011</last_update_submitted>
  <last_update_submitted_qc>February 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Seema Khan, MD</name_title>
    <organization>Northwestern University</organization>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

